scholarly journals Association between vitamin D metabolites, vitamin D binding protein, and proteinuria in dogs

2020 ◽  
Vol 34 (6) ◽  
pp. 2468-2477
Author(s):  
Matthew S. Miller ◽  
Adam J. Rudinsky ◽  
Brett G. Klamer ◽  
Dennis J. Chew ◽  
Valerie J. Parker
Keyword(s):  
Vitamin D ◽  
Binding Protein ◽  
Vitamin D Metabolites ◽  
Vitamin D Binding Protein

Vitamin D-binding protein: multifunctional component of blood serum

2021 ◽  
Vol 76 (1) ◽  
pp. 103-110
Author(s):  
Alexandra A. Povaliaeva ◽  
Ekaterina A. Pigarova ◽  
Anastasia A. Romanova ◽  
Larisa K. Dzeranova ◽  
Artem Y. Zhukov ◽  
...  
Keyword(s):  
Vitamin D ◽  
Binding Sites ◽  
Binding Protein ◽  
Vitamin D Metabolites ◽  
Biological Functions ◽  
Vitamin D Binding Protein ◽  
Fatty Acid Binding ◽  
Physiological Properties ◽  
Steroid Binding ◽  
Tumor Pathogenesis

Vitamin D-binding protein (DBP) was discovered more than half a century ago as a polymorphic serum protein and is currently characterized by a variety of physiological properties. First of all, DBP carries the bulk of vitamin D metabolites circulating in the bloodstream, while albumin is the second most important transport protein, especially in patients with a low concentration of DBP in serum. Since it was discovered that only 12% of the total circulating DBP have occupied steroid binding sites, a vigorous study of other potential biological roles of DBP was initiated: actin utilization, regulation of inflammation and innate immunity mechanisms, fatty acid binding, effects on bone metabolism and participation in the tumor pathogenesis. This review focuses on the main known biological functions of DBP.

Use of surface plasmon resonance in the binding study of vitamin D, metabolites and analogues with vitamin D binding protein

2017 ◽  
Vol 409 (10) ◽  
pp. 2547-2558 ◽  
Author(s):  
Pilar Canoa ◽  
Marcos L. Rivadulla ◽  
Jonathan Popplewell ◽  
René van Oosten ◽  
Generosa Gómez ◽  
...  
Keyword(s):  
Vitamin D ◽  
Surface Plasmon Resonance ◽  
Surface Plasmon ◽  
Plasmon Resonance ◽  
Binding Protein ◽  
Binding Study ◽  
Vitamin D Metabolites ◽  
Vitamin D Binding Protein

Vitamin D metabolism in osteoporotic women during treatment with estrogen, an anabolic steroid, or calcitonin

1990 ◽  
Vol 122 (6) ◽  
pp. 715-721 ◽  
Author(s):  
Dorthe Hartwell ◽  
Christian Hassager ◽  
Kirsten Overgaard ◽  
Bente Juel Riis ◽  
Jan Pødenphant ◽  
...  
Keyword(s):  
Vitamin D ◽  
Serum Concentration ◽  
Binding Protein ◽  
Total Serum ◽  
Vitamin D Metabolites ◽  
Nandrolone Decanoate ◽  
Vitamin D Binding Protein ◽  
Double Blind ◽  
Vitamin D Metabolism ◽  
Norethisterone Acetate

Abstract. We assessed the effects of a continuous oral combination of estradiol and norethisterone acetate, nandrolone decanoate, or salmon calcitonin on the vitamin D endocrine system. One hundred and nineteen postmenopausal women, aged 55-75 years, with at least one osteoporotic fracture, were randomly allocated to one year of treatment with estradiol and norethisterone acetate, nandrolone decanoate, or calcitonin, all drugs with a beneficial effect on bone. All three trials were double-blind and placebo-controlled; 104 women (87%) completed the study. We measured the total serum concentration of 1,25-dihydroxyvitamin D (1,25(OH)2D) and vitamin D-binding protein, and estimated the free 1,25(OH)2D index and the "24-hydroxylase activity" initially, and at 6 and 12 months. Furthermore, the 24-h urinary excretions of calcium, phosphate, and adenosine 3'-5'-cyclic monophosphate were assessed initially and at 12 months. The serum concentration of vitamin D-binding protein and 1,25(OH)2D increased transiently during estradiol and norethisterone acetate treatment and vitamin D-binding protein decreased transiently during nandrolone decanoate treatment. None of the other parameters were significantly affected by any of the three treatments. The risk of type II errors was below 10 per cent for all vitamin D measurements. We conclude that the vitamin D metabolites are unlikely to be of major importance for the mechanism by which these drugs exert their positive skeletal effects.

scholarly journals MON-372 Treatment-Resistant Vitamin D Deficiency: Is It a Vitamin D Binding Protein Issue?

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Sirisha Thambuluru ◽  
Imran Unal ◽  
Stuart Frank ◽  
Amy Warriner ◽  
Fernando Ovalle ◽  
...  
Keyword(s):  
Vitamin D ◽  
Alkaline Phosphatase ◽  
Vitamin D Deficiency ◽  
Binding Protein ◽  
High Dose ◽  
Vitamin D Metabolites ◽  
Vitamin D Binding Protein ◽  
Treatment Resistant ◽  
Vitamin D Levels ◽  
25 Oh Vitamin D

Abstract Introduction Vitamin D is present in free and bound forms; the bound form is complexed mainly to vitamin D binding protein (DBP). Vitamin D levels are affected by age, pregnancy, liver disease, obesity, and DBP mutations. We report a patient with treatment-resistant vitamin D deficiency suggestive of a DBP with abnormal vitamin D binding. Clinical Case A 58-year-old Pakistani male with a history of hypertension, sleep apnea and hypogonadism presented to endocrine clinic with symptoms including fatigue, generalized muscle cramps, and joint pain. Evaluation of common causes of fatigue, such as anemia, thyroid dysfunction and adrenal insufficiency were ruled out with CBC, thyroid hormone levels and ACTH stimulation test results all within normal ranges. A 25-OH vitamin D level was profoundly low (4.2 ng/ml; normal 30-100), and a 1,25-OH vitamin D level was undetectable (<8 pg/ml; normal 18-72), leading to a presumptive diagnosis of severe vitamin D deficiency. However, his calcium, phosphorus, alkaline phosphatase and kidney function were in the normal range. Furthermore, the absence of osteoporosis, fracture history, or kidney stones suggested adequate vitamin D action at target tissues; PTH levels were high-normal to minimally elevated, ranging 70-94 pg/ml (12-88pg/mL). Aggressive supplementation with vitamin D3 at 50,000 IU 3 times a week and 5,000 IU daily failed to normalize 25-OH vitamin D (ranged 4.6-10ng/ml; normal 30-100) and 1,25-OH vitamin D levels remained undetectable. Addition of calcitriol resulted in mild hypercalcemia and was discontinued. Malabsorption did not appear to be a contributing factor, as a negative tTG antibody (with normal IgA) excluded celiac disease. Vitamin D metabolites levels measured with mass spectrometry showed undetectable 25-OH vitamin D levels (D2 <4 ng/ml, D3 <2 ng/ml; total <6ng/ml; normal 20-50) and 1,25-OH vitamin D levels (<8 pg/ml). Urine N-telopeptide, 24-hour urine calcium (177mg; 100-240) and bone-specific alkaline phosphatase were all normal. Repeat testing over more than five years showed similar results. DBP levels of 269 ug/ml [104-477] excluded DBP deficiency. Clinical Lesson Vitamin D deficiency is increasingly part of routine testing in internal medicine and endocrinology clinics, as is repletion with high-dose vitamin D. However, in rare cases such as this, relying on 25-OH vitamin D levels can be misleading, and supplementation unnecessary or potentially harmful. Thus, treatment decisions should consider the full clinical context and further evaluation performed when warranted. This patient’s labs are suggestive of an abnormality in the DBP, supporting future examination using molecular testing.

scholarly journals Vitamin D Metabolites and Binding Protein Predict Preeclampsia in Women with Type 1 Diabetes

Nutrients ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 2048
Author(s):  
Clare B. Kelly ◽  
Carol L. Wagner ◽  
Judith R. Shary ◽  
Misti J. Leyva ◽  
Jeremy Y. Yu ◽  
...  
Keyword(s):  
Vitamin D ◽  
Type 1 Diabetes ◽  
Binding Protein ◽  
Vitamin D Metabolites ◽  
Vitamin D Binding Protein ◽  
Hydroxyvitamin D ◽  
Dihydroxyvitamin D ◽  
Healthy Pregnancy ◽  
25 Hydroxyvitamin D

The risk for preeclampsia (PE) is enhanced ~4-fold by the presence of maternal type 1 diabetes (T1DM). Vitamin D is essential for healthy pregnancy. We assessed the total, bioavailable, and free concentrations of plasma 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,25(OH)2D), and vitamin D binding protein (VDBP) at ~12, ~22, and ~32 weeks’ gestation (“Visits” (V) 1, 2, and 3, respectively) in 23 T1DM women who developed PE, 24 who remained normotensive, and 19 non-diabetic, normotensive women (reference controls). 25(OH)D deficiency was more frequent in diabetic than non-diabetic women (69% vs. 22%, p < 0.05), but no measure of 25(OH)D predicted PE. By contrast, higher 1,25(OH)2D concentrations at V2 (total, bioavailable, and free: p < 0.01) and V3 (bioavailable: p < 0.05; free: p < 0.01), lower concentrations of VDBP at V3 (p < 0.05), and elevated ratios of 1,25(OH)2D/VDBP (V2, V3: p < 0.01) and 1,25(OH)2D/25(OH)D (V3, p < 0.05) were all associated with PE, and significance persisted in multivariate analyses. In summary, in women with T1DM, concentrations of 1,25(OH)2D were higher, and VDBP lower, in the second and third trimesters in women who later developed PE than in those who did not. 1,25(OH)2D may serve as a new marker for PE risk and could be implicated in pathogenesis.

Circulating vitamin D binding protein levels are not associated with relapses or with vitamin D status in multiple sclerosis

2013 ◽  
Vol 20 (4) ◽  
pp. 433-437 ◽  
Author(s):  
Joost Smolders ◽  
Evelyn Peelen ◽  
Mariëlle Thewissen ◽  
Paul Menheere ◽  
Jan Damoiseaux ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Vitamin D ◽  
Binding Protein ◽  
High Dose ◽  
Vitamin D Metabolites ◽  
Vitamin D Status ◽  
Vitamin D Binding Protein ◽  
Vitamin D Metabolism ◽  
Physiological Range ◽  
High Dose Vitamin

Background: A low vitamin D status has been associated with multiple sclerosis (MS). Most circulating vitamin D metabolites are bound to vitamin D binding protein (DBP). Objectives: The purpose of this study was to explore whether there is an association between MS and DBP. Methods: We compared DBP concentrations in blood samples of controls ( n = 30) and subjects with relapsing–remitting MS (RRMS) during remission ( n = 29) and relapse ( n = 15). Furthermore, we explored correlations of DBP with 25- hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D levels (1,25(OH)2D), and the effect of high-dose vitamin D3 supplementation on DBP levels in RRMS patients ( n = 15). Results: DBP-concentration did not differ between the sub-groups measured, and there was no correlation between DBP and vitamin D metabolite concentration within the physiological range. Upon supplementation of high doses vitamin D3, DBP concentration remained unaltered. After supplementation, serum 1,25(OH)2D( R = 0.517, p = 0.049), but not 25(OH)D, correlated positively with DBP. Conclusions: We found no association between DBP, MS, and vitamin D status within the physiological range. After high - dose vitamin D supplementation, DBP concentrations may be relevant for vitamin D metabolism.

Recommendations on the measurement and the clinical use of vitamin D metabolites and vitamin D binding protein – A position paper from the IFCC Committee on bone metabolism

2021 ◽  
Vol 517 ◽  
pp. 171-197
Author(s):  
Konstantinos Makris ◽  
Harjit P Bhattoa ◽  
Etienne Cavalier ◽  
Karen Phinney ◽  
Christopher T. Sempos ◽  
...  
Keyword(s):  
Vitamin D ◽  
Bone Metabolism ◽  
Binding Protein ◽  
Protein A ◽  
Position Paper ◽  
Vitamin D Metabolites ◽  
Clinical Use ◽  
Vitamin D Binding Protein

scholarly journals Association of blood lead level with vitamin D binding protein, total and free 25-hydroxyvitamin D levels in middle school children

2021 ◽  
pp. 1-28
Author(s):  
Abdur Rahman ◽  
Reem Al-Sabah ◽  
Reem Jallad ◽  
Muddanna S. Rao
Keyword(s):  
Vitamin D ◽  
Blood Lead Level ◽  
Binding Protein ◽  
Lead Level ◽  
Blood Lead ◽  
Negative Association ◽  
Vitamin D Metabolites ◽  
Vitamin D Binding Protein ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

Abstract A negative association between blood lead level (BPbL) and vitamin D metabolites in occupationally exposed populations has been reported but data from the general population are scarce. Furthermore, the association between BPbL and vitamin D binding protein (DBP) and free 25-hydroxyvitamin D [25(OH)D] has not been reported. We investigated the association of BPbL with DBP, total and free 25(OH)D in healthy adolescents (N=1347; age range 11-16 years) cross-sectionally selected from all Governorates of Kuwait, utilizing multi-stage cluster random sampling. Pb in whole blood was analyzed by inductively coupled plasma mass spectrometry, and DBP with ELISA. Plasma 25(OH)D was analyzed by LC-MS/MS and free 25(OH)D was calculated utilizing the levels and binding affinities of DBP and albumin for 25(OH)D. DBP was positively associated with BPbL [β (95%CI)= 0.81 (0.14 −0.22); p< 0.001]. A negative association between BPbL and total 25(OH)D was non-significant (p=0.24) when BPbL was used as continuous variable but was significant when used as quartiles (p=0.02). The negative association between BPbL and free 25(OH)D was significant whether BPbL was used as continuous, as quartiles or as cut-off point of <5µg/dL. In multinomial logistic regression, the odds of vitamin D insufficiency and deficiency were more than two-fold higher in the upper quartiles of BPbL compared to the lowest quartile. The negative correlation of BPbL with free 25(OH)D was more robust than its correlation with total 25(OH)D. Future studies must consider the levels of DBP when assessing the association between Pb and vitamin D metabolites.

Sign in / Sign up

Export Citation Format

Share Document